Associated Press | Lincolnshire-based BioSante Pharmaceuticals said Friday its first-quarter loss widened
on higher development costs for its drug candidate LibiGel. The company lost $10.5 million, or 19 cents per share, compared
with a loss of $4.1 million, or 15 cents per share, during the same
period a year prior. The company did not report revenue.

BioSante said the potential drug LibiGel is in three late-stage
clinical trials. It is intended to treat sexual dysfunction in women.
LibiGel is a testosterone gel applied to the skin.